Lead Sponsor

OPKO Health, Inc.

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients with subfoveal predominantly classic, minimally classic and purely occult lesions, secondary to age related macular degeneration, with a total lesion size (including blood, atrophy/scar and neovascularization) of \< 12 total disc areas, of which at least 50% are active CNV.
•Patients must have visual acuity 20/50 to 20/320 in the study eye.
•Patients must have better visual acuity in the fellow eye than the study eye.
•Subretinal hemorrhage (if any) must comprise no more than 50% of total lesion size.

•Patients with concomitant eye disease, including glaucoma, uveitis, diabetic retinopathy, presence of pigment epithelial tears or rips, acute ocular or periocular infection in the study eye.
•Patients with \> 3 prior PDT treatments with Visudyne in the study eye.
•Patients who received PDT in the study eye within eight weeks prior to the baseline angiography/photography.

Related studies

NCT05803785 · Age-Related Macular Degeneration

NCT07392255 · Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT07550777 · Diabete Mellitus, Retina Vein Occlusion, and more

NCT07440225 · Macular Degeneration, Age-Related Macular Degeneration, and more

NCT05407636 · AMD, nAMD, and more

Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5